5535-03-5

Basic information

• Product Name: 4-(2-Oxiranylmethoxy)benzoic Acid Methyl Ester
• Synonyms: 4-(2-Oxiranylmethoxy)benzoic Acid Methyl Ester;Benzoic acid, 4-(oxiranylMethoxy)-, Methyl ester;Methyl 4-(2,3-Epoxypropoxy)benzoate;4-(2,3-epoxypropyloxy)Methyl benzoate
• CAS NO: 5535-03-5
• Molecular Formula: C₁₁H₁₂O₄
• Molecular Weight: 208.21058
• Product Categories: Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 5535-03-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 330.5°C at 760 mmHg
• Flash Point: 146.6°C
• Appearance: /
• Density: 1.213g/cm³
• Vapor Pressure: 0.000166mmHg at 25°C
• Refractive Index: 1.536
• Solubility: Chloroform, Dichloromethane, Ethyl Acetate
• CAS DataBase Reference: 4-(2-Oxiranylmethoxy)benzoic Acid Methyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-Oxiranylmethoxy)benzoic Acid Methyl Ester(5535-03-5)
• EPA Substance Registry System: 4-(2-Oxiranylmethoxy)benzoic Acid Methyl Ester(5535-03-5)

Safety Data

• Hazardous Substances Data: 5535-03-5(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

4-(2-Oxiranylmethoxy)benzoic Acid Methyl Ester is a intermediate in the production of tyrosinase-inhibitors used in skin lightening cosmetics.

InChI:InChI=1/C11H12O4/c1-13-11(12)8-2-4-9(5-3-8)14-6-10-7-15-10/h2-5,10H,6-7H2,1H3

Upstream product

• 99-76-3 methyl 4-hydroxylbenzoate 
• 106-89-8 epichlorohydrin 
• 99-96-7 4-hydroxy-benzoic acid 

Downstream Products

• 60377-30-2 4-[3-(4-tert-Butyl-phenylamino)-2-hydroxy-propoxy]-benzoic acid methyl ester 
• 5255-93-6 methyl 4-(3-phenyl-2-oxo-5-oxazolidinyl)methoxybenzoate 
• 50448-58-3 C₂₆H₃₆N₂O₈ 
• 85850-50-6 4-[2-Hydroxy-3-(2-pyrrolidin-1-yl-ethylamino)-propoxy]-benzoic acid methyl ester 
• 85850-51-7 4-[2-Hydroxy-3-(2-piperidin-1-yl-ethylamino)-propoxy]-benzoic acid methyl ester 
• 85850-52-8 4-[2-Hydroxy-3-(2-morpholin-4-yl-ethylamino)-propoxy]-benzoic acid methyl ester 
• 33947-97-6 4-(2-Hydroxy-3-isopropylamino-propoxy)-benzoic acid methyl ester 
• 51698-62-5 1-(4-methoxycarbonylphenoxy)-2-hydroxy-3-tert-butylamino propane 
• 87645-63-4 1-(4'-Methoxycarbonylphenoxy)-3-(2'',6''-dimethylpiperidino)-propan-2-ol 
• 5256-01-9 methyl 4-[3-(4-chlorophenyl)-2-oxo-5-oxazolidinyl]methoxybenzoate 
• 154871-09-7 methyl 4-[3-(4-nitrophenyl)-2-oxo-5-oxazolidinyl]methoxybenzoate 
• 5256-11-1 methyl 4-[3-(4-methylphenyl)-2-oxo-5-oxazolidinyl]methoxybenzoate 
• 154871-21-3 methyl 4-[3-(4-fluorophenyl)-2-oxo-5-oxazolidinyl]methoxybenzoate 
• 154871-28-0 methyl 4-[3-(4-methoxyphenyl)-2-oxo-5-oxazolidinyl]methoxybenzoate 

Relevant articles and documents

Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity

Lysine demethylases play an important role in epigenetic regulation and thus in the development of diseases like cancer or neurodegenerative disorders. As the lysine specific demethylase 1 (LSD1/KDM1) has been strongly connected to androgen and estrogen dependent gene expression, it serves as a promising target for the therapy of hormone dependent cancer. Here, we report on the discovery of new small molecule inhibitors of LSD1 containing a propargylamine warhead, starting out from lysine containing substrate analogues. On the basis of these substrate mimicking inhibitors, we were able to increase potency by a combination of similarity-based virtual screening and subsequent synthetic optimization resulting in more druglike LSD1 inhibitors that led to histone hypermethylation in breast cancer cells.

SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF SOME 1-PHENOXY-3-AMINO-PROPAN-2-OLS

-

Ultra-Short-Acting β-Adrenergic Receptor Blocking Agents. 2. (Aryloxy)propanolamines Containing Esters on the Aryl Function

Several short-acting β-adrenergic receptor blocking agents have been prepared by incorporating ester functions into the aryl portion of certain (aryloxy)propanolamine systems.In particular, methyl 3-phenyl>propionate hydrochloride (ASL-8052) was found to be a moderately potent, cardioselective compound with a short duration of action when determined in in vivo canine models.